Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECISION-CAL
NCT05845424Phase 4Recruiting
- Sponsor
- Samsung Medical Center
- Start
- Jul 2023
- Primary completion
- Jun 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rosuvastatin and ezetimibe in Coronary artery calcification (CAC) (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Major adverse cardiovascular events at 4.5 years. Started Jul 2023; status: recruiting.
02
Drugs
rosuvastatinezetimibe
03
Conditions
Coronary artery calcification (CAC)
Beyond the preview
Go deeper on NCT05845424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05845424.